← Back to Search

MRI Software and Techniques

RSI-MRI for Early Detection of Prostate Cancer (IMAGINED Trial)

N/A
Recruiting
Led By Michael A Liss, MD, PhD
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to approximately 9 months
Awards & highlights

Summary

This trial will explore if MRI tech can help spot early prostate cancer, improving accuracy of biopsies.

Who is the study for?
This trial is for men selected to undergo an MRI-guided prostate needle biopsy. Participants must be able to understand and agree to the study's procedures by providing informed consent.
What is being tested?
The IMAGINED Trial is testing if advanced MRI software, called Restricted Spectrum Imaging-MRI (RSI-MRI), can improve early detection of prostate cancer during a biopsy procedure.
What are the potential side effects?
Since this trial involves imaging techniques rather than drugs, side effects are minimal but may include discomfort from lying still during the MRI or from the biopsy procedure itself.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to approximately 9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to approximately 9 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
RSM mapping value

Trial Design

3Treatment groups
Experimental Treatment
Group I: MRI imaging using Siemens MRIExperimental Treatment1 Intervention
Participants enrolled will undergo routine Magnetic Resonance Imaging (MRI) to obtain Restricted Spectrum Mapping (RSM). These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.
Group II: MRI imaging using Phillips MRIExperimental Treatment1 Intervention
Participants enrolled will undergo routine MRI to obtain RSM. These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.
Group III: MRI imaging using General Electric (GE) MRIExperimental Treatment1 Intervention
Participants enrolled will undergo routine MRI to obtain RSM. These sequences are acquired at the same time as standard multi-parametric MRI sequences. Second post-processing software then transfers the acquired RSI images from DICOM format and applies a color-coded image that is then overlayed onto the anatomic T2 image.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,775 Total Patients Enrolled
566 Trials studying Prostate Cancer
529,584 Patients Enrolled for Prostate Cancer
The University of Texas Health Science Center at San AntonioLead Sponsor
467 Previous Clinical Trials
91,539 Total Patients Enrolled
12 Trials studying Prostate Cancer
3,000 Patients Enrolled for Prostate Cancer
Michael A Liss, MD, PhDPrincipal InvestigatorUniversity of Texas Health Science Center San Antonio
1 Previous Clinical Trials
50 Total Patients Enrolled
1 Trials studying Prostate Cancer
50 Patients Enrolled for Prostate Cancer

Media Library

Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI) (MRI Software and Techniques) Clinical Trial Eligibility Overview. Trial Name: NCT05882253 — N/A
Prostate Cancer Research Study Groups: MRI imaging using General Electric (GE) MRI, MRI imaging using Siemens MRI, MRI imaging using Phillips MRI
Prostate Cancer Clinical Trial 2023: Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI) Highlights & Side Effects. Trial Name: NCT05882253 — N/A
Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI) (MRI Software and Techniques) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05882253 — N/A
~150 spots leftby Dec 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top